Glioma Pipeline Drugs Assessment

Glioma Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Overview:

Glioma refers to the broad category of the brain and spinal cord tumors, arises from the glial cells of the brain. Many types of gliomas based on the brain cell,Astrocytomas, Ephindryomas,andOligodendrogliomas.

The symptoms, prognosis,and treatment of the gliomadepend on the patientâ€™s age, exact type of tumor and location of tumor within brain. Chemotherapy or targeted drug therapy usually suggest for the treatment of glioma. Furthermore, treatment may include radiation therapy followed by surgery.

Segmentation:

By glioma type, glioma pipeline drugs are segmented into

Ephidryomas
Astrocytomas
Oligodendrogliomas

By grade, glioma pipeline drugs are segmented into

High-Grade Glioma
Low-Grade Glioma

By trial phase, glioma pipeline drugs are segmented into

Preclinical Studies
Phase-I
Phase-II
Phase-III
Phase-IV

By company, glioma pipeline drugs are segmented into

GW Pharmaceuticals (UK)
Daiichi Sankyo Company (Japan)
Sapience Therapeutics, Inc. (U.S.)
Tocagen (U.S.)
Vaximm AG (Switzerland)
Tocagen (U.S.)

Space Analysis:

In March 2017, Sapience Therapeutics, Inc., announced that its lead candidate, ST-36, received orphan drug designation by the U.S. FDA the treatment of glioma.
In September 2017, VAXIMM AG announced that the Companyâ€™s lead product candidate, VXM01, received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma.

Report Description:

Glioma Pipeline Drugs Assessment report studies the various therapeutics under clinical development for glioma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the glioma pipeline drugs development. This report studies the dynamics of the Glioma Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on glioma pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Key Features of the Report:

Provides the information related to universities and research institutes working in the therapeutics development
Report comprehensively covers the all active and discontinued studies
Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
Presents the prominent targets for drug development in each stage of clinical trial
Provides the in-depth analysis onthe each drug candidates in the clinical trial phases

Location

GEOGRAPHY

Key Features of the Reports

The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
The report tracks recent innovations, key developments and startup’s details that are actively working in the market
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

GW Pharmaceuticals (UK)
Daiichi Sankyo Company (Japan)
Sapience Therapeutics, Inc. (U.S.)
Tocagen (U.S.)
Vaximm AG (Switzerland)
Tocagen (U.S.)

Purchase Option